Human Papillomavirus Vaccination for Recalcitrant Cutaneous Warts
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
•Recalcitrant warts affect immunocompetent and immunocompromised persons.•The optimal approach to refractory warts remains unclear.•Human papillomavirus vaccination is a promising therapy for recalcitrant warts.
References
1.
Leiding J, Holland S
. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012; 130(5):1030-48.
PMC: 3517887.
DOI: 10.1016/j.jaci.2012.07.049.
View
2.
Shin J, Son J, Lee J, Kim H, Ko H, Kim B
. Nonavalent human papilloma virus vaccine for the treatment of multiple recalcitrant warts: An open-label study. J Am Acad Dermatol. 2021; 86(4):940-941.
DOI: 10.1016/j.jaad.2021.03.074.
View
3.
Yang M, Son J, Kim G, Kim H, Ko H, Kim M
. Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients. J Dermatolog Treat. 2018; 30(4):405-409.
DOI: 10.1080/09546634.2018.1527006.
View
4.
Waldman A, Whiting D, Rani M, Alam M
. HPV Vaccine for Treatment of Recalcitrant Cutaneous Warts in Adults: A Retrospective Cohort Study. Dermatol Surg. 2019; 45(12):1739-1741.
DOI: 10.1097/DSS.0000000000001867.
View
5.
Leung L
. Recalcitrant nongenital warts. Aust Fam Physician. 2011; 40(1-2):40-2.
View